MHRA(UK) has approved the subcutaneous version of Ocrevus (ocrelizumab subcutneous) to treat patients with relapsing and primary progressive multiple sclerosis
The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Roche's subcutaneous version of Ocrevus (ocrelizumab subcutaneous) to treat patients with relapsing and primary progressive multiple sclerosis
Previously approved in the U.K. as an infusion, the drug can now be given as a subcutaneous injection by a doctor or nurse every six months. In a randomized study of 236 patients, patients who received a single dose of the injected drug had similar levels of medicine in the blood as those who received two infusions. Elsewhere, regulators in Europe granted subcutaneous Ocrevus an approval last month.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins